Analysis On Clinical Effect Of CIK Combined With TKIs In Treatment Of Non-small Cell Lung Cancer Patients With TKIs Resistance

Objective:To observe the therapeutic effect and progression free survival of EGFR-TKIs combined with DC-CIK on Advanced Non-small Cell Lung Cancer patients who had gradual progression after EGFR-TKIs treatment.Methods:Retrospective review is conducted on 35 cases of advanced NSCLC patients who experienced treatment failure of EGFR-TKIs.Divided into 3 groups,group A:continued to TKI treatment,include 15 cases;group B:accepted EGFR-TKIs and DC-CIK combination less than 4 courses treatment include 10 cases;group C:accepted EGFR-TKIs and DC-CIK combination more than or equal to 4 cycles therapy,include 10 cases.Compare the response rate,progression free survival and the life quality of three groups,and make a statistics analysis.Results:1.Treatment effect:Clinical benefit rates of three groups are 73.3%、80%、90%。2.Progression free survival:The median progressive free survival of combined with DC-CIK more than or equal to 4 cycles treatment group compared with continued EGFR-TKIs treatment group was significantly prolonged(12.5 months vs 5.2months,P=0.029);Compared with the combined with DC-CIK less than 4 periods treatment group,the m PFS of more than or equal to 4 cycles therapy group was obviouslyprolonged(12.5 months vs 8.5 months,P=0.007);The m PFS of combined with DC-CIK less than 4 courses treatment group is better than EGFR-TKIs maintenance therapy group,but the difference was not statistically significant(8.5 months vs 5.2months,P=0.906).3.Quality of life:Appetite,spirit,sleep,fatigue and other life quality scores of the EGFR-TKIs and DC-CIK combination more than or equal to 4 courses therapy group was superior than continued group,the distinction had statistical significance(P <0.05);The scores of combined DC-CIK less than 4 periods treatment group have amelioration,compared with EGFR-TKIs maintenance therapy group,but the two groups without significant difference in statistics(P>0.05),The scores of more than or equal to 4circles combination therapy group was improved,compared with combined treatment group of less than 4 cycles,but difference in scores of no statistical significance(P >0.05).4.Adverse reactions:The main adverse reactions of EGFR-TKIs and DC-CIK combination therapy groups were fever,skin rash and other somatic cell side effects.No severe adverse reactions appeared.Conclusion:1.DC-CIK and EGFR-TKIs combination therapy can further effective control for TKIs secondary resistance disease progression.2.DC-CIK combined with EGFR-TKIs can significantly extend the patients’ PFS who had gradual progression after EGFR-TKIs,and the clinical benefit of patients with DC-CIK therapy 4 cycles is bigger,and without increase adverse reactions.